4 April 2014  - NICE has announced it intends to recommend alemtuzumab for adults with active relapsing remitting multiple sclerosis.

There is an appeal period (until 22 April) and then NICE will issue the final guidance in June. NICE recommendations are normally enforceable three months from the date of publication, so neurologists should be able to prescribe alemtuzumab from October 2014.

This final draft guidance reverses the decision to not recommend alemtuzumab made in the previous draft consultation document issued in December. The MS Trust has been an active contributor to the review process.

For more details, go to: http://www.mstrust.org.uk/news/article.jsp?id=6251